left

 

 

Investor Relations

Nutri-Pharmaceuticals Research, Inc. Announces Engagement of Auditing Firm
Tuesday August 21, 9:00 am ET

LAS VEGAS--(BUSINESS WIRE)--Nutri-Pharmaceuticals Research, Inc. (Pink Sheets: NRPR - News) is pleased to announce the engagement of S. W. Hatfield, CPA as the Company's Registered Independent Certified Public Accounting Firm.
ADVERTISEMENT

On June 26, 2007, upon completion of the requisite due diligence by both parties, the Company executed an engagement letter with S.W. Hatfield, CPA of Dallas, Texas, to initially audit the Company's financial statements as of and for the respective years ended December 31, 2005 and 2006, and to provide ongoing auditing and other required assurance services to the Company.

Upon the completion of the audits of its financial statements, the Company intends to register common stock with the U.S. Securities and Exchange Commission (SEC) by filing a Registration Statement under the appropriate Act. Upon the Registration Statement being declared "effective" by the SEC, the Company intends to apply to have its common stock quoted for trading on the National Association of Securities Dealers (NASD) "Over The Counter Electronic Bulletin Board." The Company may also consider, either concurrently or subsequent thereto, make an application for listing it's common stock to trade on the American Stock Exchange (AMEX), subject to meeting the AMEX's initial listing requirements.

"Registering our common stock with the SEC will put us in a position to provide our shareholders with timely and current reporting of information about our operations and financial condition. We anticipate that the availability of this type of information should instill even more confidence in our existing shareholders and potential investors," says Godfrey Yew, Chairman and CEO of Nutri Pharmaceuticals Research, Inc. "The future of the company is looking better and better each day and we are entering into a very exciting time for the company."

Nutri Pharmaceuticals Research has proprietary research and technology for converting oils to powders without altering the molecular structure of the oil in the powder state with existing sales in both domestic and international markets.

Forward looking statements

All statements contained in this Press Release, other than statements of historical facts, that address future activities, events or developments are forward-looking statements, including, but not limited to, statements containing the words "believe," "anticipate," "expect" and words of similar import. These statements are based on certain assumptions and analyses made by us in light of our experience and our assessment of historical trends, current conditions and expected future developments as well as other factors we believe are appropriate under the circumstances. However, whether actual results will conform to the expectations and predictions of management is subject to a number of risks and uncertainties that may cause actual results to differ materially.

Such risks include, among others, the following: international, national and local general economic and market conditions: our ability to sustain, manage or forecast our growth; raw material costs and availability; new product development and introduction; existing government regulations and changes in, or the failure to comply with, government regulations; adverse publicity; competition; the loss of significant customers or suppliers; fluctuations and difficulty in forecasting operating results; changes in business strategy or development plans; business disruptions; the ability to attract and retain qualified personnel; the ability to protect technology; and other factors referenced in this and previous disclosures.

Consequently, all of the forward-looking statements made in this Press Release are qualified by these cautionary statements and there can be no assurance that the actual results anticipated by management will be realized or, even if substantially realized, that they will have the expected results or consequences to or effects on our business operations.


Click here to get News Releases NPRI Reports Record First Quarter Earnings

left

 

 

 

O2P™ is a trademark of NPRI  |  ©1994 - 2009 Nutri Pharmaceuticals Research, Inc. (NPRI) Investor Relations